Lv2
106 积分 2021-07-14 加入
Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop
16小时前
待确认
Stable Disease Is a Valid End Point in Clinical Trials
1天前
已完结
Sample size considerations for Japanese patients in a multi-regional trial based on MHLW guidance
29天前
已完结
Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop
1个月前
已完结
Surrogate endpoints in clinical trials: Definition and operational criteria
1个月前
已完结
FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
1个月前
已完结
Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival
1个月前
已完结
Assessment of the efficacy and tolerability of a topical formulation containing caffeine and Procapil 3% for improvement of male pattern hair loss
2个月前
已完结
The Target Trial Framework for Causal Inference From Observational Data: Why and When Is It Helpful?
2个月前
已完结
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
